Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03467932 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Oramed.
- Completed
- Registry status
- Phase 2
- Development phase
- 373
- Enrollment target
NCT03467932 is a Phase 2 study that has completed, run by Oramed. The registered enrollment target is 373 participants.
The verdict
NCT03467932, a Phase 2 study, has completed, sponsored by Oramed.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 373 participants
- Enrollment target
Study Summary
This is a four-way (Participant, Care Provider, Investigator, Outcomes Assessor) masked (blinded) study designed to explore the efficacy of ORMD-0801 when given in different regimens across a dose range for up to 12 weeks in subjects with type 2 diabetes mellitus (T2DM).
Interventions
- DRUG Placebo oral capsule
- DRUG Cohort A: ORMD-0801
- DRUG Cohort B: ORMD-0801
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 373 participants |
| Start Date | 2018-05-29 |
| Est. Completion | 2020-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03467932
The ClinicalTrials.gov registry entry for NCT03467932 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 373 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oramed, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo oral capsule is the first listed.
NCT03467932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03467932 about?
NCT03467932 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus". This is a four-way (Participant, Care Provider, Investigator, Outcomes Assessor) masked (blinded) study designed to explore the efficacy of ORMD-0801 when given in different regimens across a dose range for up to 12 weeks in subjects with type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT03467932?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 373 participants. The study started on 2018-05-29. Estimated completion is 2020-02-18.
What interventions are being tested in trial NCT03467932?
The interventions under investigation include: Placebo oral capsule (DRUG), Cohort A: ORMD-0801 (DRUG), Cohort B: ORMD-0801 (DRUG).
Who is sponsoring clinical trial NCT03467932?
This trial is sponsored by Oramed, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.